At present, there is no effective therapy for any of the neurodegenerative amyloidoses, despite renewed efforts to identify compounds active against the various implicated pathogenetic molecules. We have screened a library of 2960 natural and synthetic compounds in two cell lines chronically infected with mouse prions, and have identified eight new inhibitors of prion replication in vitro. They belong to two distinct chemical families that have not previously been recognised as effective in the field of transmissible spongiform encephalopathies: seven are 3-aminosteroids and one is a derivative of erythromycin A with an oxime functionality. Our results suggest that these aminosteroids inhibit prion replication by triggering a common target, possibly implicated in the regulatory pathways of cellular prion protein metabolism. Furthermore, using a quantitative approach for the study of protein stability, it was shown that the erythromycin A derivative altered prion protein stability by direct interaction. Such direct targeting of this amyloid precursor might provide new clues for the understanding of prion diseases and, more importantly, help to define new molecules that are active against prion diseases.
INTRODUCTION
The abnormal accumulation of host proteins in the brain is the putative cause of many neurodegenerative disorders, called amyloidoses. They include Alzheimer's disease, Parkinson's disease, Huntington's disease, prion diseases (or transmissible spongiform encephalopathies) and a variety of other disorders (Ross & Poirier, 2004) . Amyloid deposits seem central to the observed neuropathogenesis; therefore, inhibition of protein misfolding might constitute an essential strategy for therapeutic developments. In order to evaluate possible new treatments, we focused on prion diseases as a unique and robust model of transmissible amyloidosis. These diseases still constitute a large public health issue, as four cases of transmission by blood transfusion have been documented (Brown, 2007) and there is currently no available treatment, neither curative nor preventive, for prion infection.
The search for new effective compounds is a priority. Animal models allow for low throughput screenings only, so many in silico (Heal et al., 2007; Lorenzen et al., 2005; Reddy et al., 2006) or in vitro tests have been developed. The latter include the use of cellular (Kocisko et al., 2003 (Kocisko et al., , 2005 or yeast (Bach et al., 2006) models, cell-free conversion of prion protein (PrP) (Breydo et al., 2005) , surface plasmon resonance (Kawatake et al., 2006) , scanning for intensely fluorescent targets (Bertsch et al., 2005) or filter retention assays .
Numerous compounds, such as amphotericins, sulfated polyanions, porphyrins and Congo red dye, have been reported as prospective treatments (Trevitt & Collinge, 2006) . Most of these compounds displayed very low antiprion activity in vivo, although some extended the incubation period when administered near the time of infection. Clinical trials have been conducted, with the use of quinacrine and pentosan polysulfate (PPS), but none of them appeared to be efficient or convenient (Stewart et al., 2008) . Moreover, both active and passive immunotherapies have been developed (Trevitt & Collinge, 2006) and some have recently yielded promising results (Goni et al., 2008; Song et al., 2008; Wuertzer et al., 2008) , which justifies the importance of continuing the search for new therapeutics.
In this study, we present the results of in vitro screening of a library of 2960 synthetic or natural compounds using cellular models. These compounds were assessed in a murine cellular model which identified 148 candidates that showed both low toxicity and high inhibition of the protease-resistant form of PrP (PrP res ). Further quantitative and more sensitive testing identified eight compounds that were active in two cellular models. The molecular mechanisms of these compounds were investigated in a cell-free context and in cell cultures.
METHODS
Cell cultures and antibodies. The mouse cholinergic septal neuronal cell line SN56 (Magalhaes et al., 2005) was grown in OptiMem medium supplemented with 10 % fetal calf serum (FCS) and 1 % penicillin-streptomycin (PS). The hypothalamic neuronal GT1-7 cell line (Schatzl et al., 1997) was maintained in OptiMem supplemented with 5 % FCS, 5 % horse serum and 1 % PS. Cells were inoculated with clarified homogenates from brains of mice infected with prion strains Chandler or 22L, as described elsewhere (Vilette et al., 2001 ).
Saf70, Saf83 and Bar233 were used as anti-PrP antibodies. For flow cytometry analysis, rhodamine phycoerythrine (R-PE)-conjugated anti-mouse immunoglobulin G (IgG) was used as secondary antibody.
Compound library. The Chemical Library of the Institut de Chimie des Substances Naturelles is part of the French National Chemical Library (http://chimiotheque-nationale.enscm.fr/). The 2960 synthetic or natural compounds that were studied were supplied in 96-well microtitre plates and dissolved in DMSO (1 mg ml 21 ). For subsequent tests, the 17 identified compounds and PPS were resuspended in DMSO (5 mg ml
21
).
Cell culture tests of PrP res inhibition by the selected compounds ( Supplementary Fig. S1a , available in JGV Online). For high-throughput screening, 10 4 Chandler-infected or non-infected SN56 cells were seeded in 96-well plates, with 100 ml culture medium. The following day, duplicate samples of the cells were treated with 5 and 0.25 mg ml 21 of the compounds (diluted in cell culture medium) and cells were incubated for 6 days.
The toxicity of the compounds was evaluated using the cell proliferation reagent WST-1 (Roche) and compounds presenting a low toxicity were selected.
After the removal of culture medium, cells were washed in PBS, and 50 ml lysis buffer [0.5 % (w/v) sodium deoxycholate, 0.5 % (w/v) Triton X-100, 50 mM Tris/HCl, pH 7.4] was added. After 10 min at 4 uC, lysates were treated with 500 ng proteinase K (PK) for 30 min at 37 uC; PK activity was stopped by the addition of PMSF (0.8 mM final concentration). Samples were applied under vacuum to nitrocellulose membranes via a 96-well dot-blot apparatus. The membrane was then immersed in guanidium thiocyanate (4.23 M in PBS) for 10 min. After rinses in PBS and PBS-Tween buffer (PBS plus 0.1 % Tween-20), the membrane was blocked in 5 % (w/v) fat-free milk and processed with Saf70, Saf83 or Bar233 anti-PrP antibodies, and anti-mouse horseradish peroxidase-coupled secondary antibody. Bands were visualised by using the ECL kit (Amersham) with the autoradiographic method. This technique was validated using PPStreated cells as positive controls, while non-treated and DMSOtreated cells were used as negative controls (these presented a similarly strong PrP res signal).
Toxicity analyses. In 96-well plates, 10 4 SN56 cells and 2.10 4 GT1-7 cells were seeded in 100 ml culture medium. They were treated with a range of dilutions of the identified compounds and viability was assessed 6 days later by a WST-1 test. Cytotoxic dose (CD 50 ) was then estimated graphically.
For precise evaluation of the induction of apoptosis, cells were treated overnight, and apoptosis and cell death were investigated by using the Vybrant Apoptosis Assay kit no. 2 (Molecular Probes), according to the manufacturer's instructions.
Western blot to confirm the PrP res inhibitory activity of the identified compounds ( Supplementary Fig. S1b ). SN56 and GT1-7 cells were treated with two concentrations of the previously identified compounds (at 5 and 1 mg ml 21 ), with DMSO (0.5 and 0.1 %) and PPS (5 mg ml 21 ). After 6 days, cells were treated with trypsin and lysed for 10 min at 4 uC. Nuclei and cellular remnants were removed by centrifugation at 100 000 g for 2 min. The amount of protein was determined using bicinchoninic acid protein assay (Uptima). Samples were PK-treated for 30 min at 37 uC, 1 mM PMSF was added and proteins were centrifuged at 21 000 g for 1 h at 4 uC. The pellets were resuspended and heated for 5 min at 100 uC in 25 ml Laemmli buffer.
Samples were separated by SDS-PAGE (12 %) and electroblotted onto nitrocellulose membranes in transfer buffer (12 mM Tris, 80 mM glycine, 10 % 2-propanol) at 20 V overnight. The membrane was blocked and visualized exactly as described for the dot-blot method. The intensities of PrP res signals were assessed by densitometry using the ImageJ freeware (NIH) and samples were normalized with blank controls, allowing the determination of IC 50 using the same method that was used to estimate CD 50 .
prnp gene expression, and surface and total PrP quantification. SN56 and GT1-7 cells were treated overnight and dissociated using Accutase (Invitrogen). For prnp gene analysis, RNA was extracted using the RNeasy kit (Qiagen). First strand cDNA was prepared from total RNA (10 mg) using Superscript II RT (Invitrogen) according to the manufacturer's instructions. Expression levels of prnp were evaluated by quantitative PCR (qPCR), using prnp primers (59-GCTTGTTCCTTCGCATTCTC-39 and 59-GGGTATTAGCCTATGG-GGGA-39) and 18S RNA primers (59-GTAACCCGTTGAACCCCATT-39 and 59-CCATCCAATCGGTAGTAGCG-39) and iQ SYBR-Green Supermix (Bio-Rad). qRT-PCR was carried out using the 2 -DDCt method (Livak & Schmittgen, 2001 ) and normalized to 18S RNA levels as standard.
For surface PrP analysis, cells were resuspended in PBS containing Bar233 antibody (1 mg ml 21 ). After two washes, they were incubated with R-PE anti-IgG antibody (Dako; 1/15 dilution). Cells were rinsed in PBS and flow cytometry was conducted on a FACScan. Data were analysed using FlowJo software. For the phosphatidylinositol-specific phospholipase C (PI-PLC) release assay, cells were incubated for 30 min at 37 uC with 0.5 U PI-PLC and washed in PBS prior to PrP labelling.
For total PrP quantification, cells were lysed with lysis buffer containing protease inhibitor, and protein concentrations were normalized. Total PrP was quantified by ELISA according to a previously described protocol (Grassi et al., 2001) , modified to detect murine PrP. Budesonide, a previously described steroid (Kocisko et al., 2003) that also shows PrP res inhibition in SN56 cells, and cholesterol, a nontreating steroid (Bate et al., 2004) , were used as controls.
Fluorescence-based thermal shift assay of PrP. Purified recombinant murine PrP (10 mg) [produced in Escherichia coli, in 20 mM MOPS, pH 7.4, according to the method described by Rezaei (Senisterra et al., 2008) . SYPRO Orange is highly fluorescent when bound to hydrophobic sites on unfolded proteins and non-fluorescent in aqueous solution, where fluorescence is quenched. Samples were denatured by transfer from 25 to 95 uC at 3 uC min 21 , and SYPRO Orange fluorescence was monitored realtime, on an Applied Biosystems 7900HT Fast Real-Time PCR system. PrP was denatured by heat and the exposure of hydrophobic sites was quantified by fluorescence. Varying quantities of recombinant murine PrP (PrP rec ), different buffers (Tris/HCl, MOPS, phosphate buffer, MES) with or without salts (KCl, NaCl or MgCl 2 ) or glycerol, at various concentrations and pH values (ranging from 4.5 to 11) were tested. The results were reproducible, particularly for phosphate buffer (50 mM, pH 8) with NaCl at physiological concentrations (150 mM). This buffer was used for the results presented here.
RESULTS

I. Screening the 2960 synthetic or natural compounds
In order to investigate the potential of the compounds to act as anti-PrP res treatments, we developed a dual test which allowed the parallel determination of the toxicity and the PrP res inhibition ability of the compounds ( Supplementary Fig. S1 ).
Primary screen of the 2960 compounds. This double evaluation was conducted on SN56, a mouse cholinergic septal neuronal cell line, chronically infected by the Chandler scrapie strain. We used a test of cellular viability based upon the analysis of mitochondrial activity to exclude the toxic compounds. To test the inhibitory effect of the 2960 compounds, a high-throughput screening test was used on SN56 Chandler-infected cells. PrP res from infected cells was readily detected after adequate PK treatment using dotblot. The method was validated using infected cells treated with PPS, a known anti-PrP compound (Trevitt & Collinge, 2006) . For preliminary high-throughput screening, we tested the molecules at 5 and 0.25 mg ml
21
, to avoid any potential effects of DMSO (Tatzelt et al., 1996) and to evaluate a large range of concentrations. Of the 2960 compounds, 148 compounds showed both low toxicity and notable PrP res inhibition activity.
Validating the primary hits. To validate these compounds, their anti-PrP res activities were further tested using Western blot analyses, within a smaller range of dilutions (1 and 5 mg ml 21 ), since very few compounds were efficient at 0.25 mg ml
. Of the 148 compounds, PrP res was not visualised on Western blot analysis of 17 of these (data not shown), indicating that they presented anti-PrP res activity. To assess the in vitro anti-PrP res activity further, these hits were tested in another cell line, GT1-7, which is chronically infected by mouse-adapted scrapie strain 22L, using the same Western blot techniques and concentration range. After a 2-week treatment, no PrP res was observed in samples treated with eight compounds (data not shown); these were called compounds #1-#8. PrP res was not detected after up to 12 passages (around 50 days) (Fig. 1) . We did not observe any DMSO effects at the concentrations used.
The structures of these eight compounds are presented in Fig. 2 . They belong to two distinct chemical classes: seven molecules are 3-aminosteroids and the eighth is a derivative of erythromycin A. Neither erythromycin A nor five of its derivatives in the chemical library showed any significant effect. Moreover, nearly 200 steroids (including aminosteroids) with structural similarities to the seven aminosteroids were tested with similarly negative results.
Characterizing the activity and toxicity of compounds #1-#8. After validation of these eight hits, CD 50 and IC 50 were determined to evaluate which could present the most therapeutic interest. Cellular viability after treatment with serial dilutions of the compounds was assessed ( Supplementary Fig. S2 and Table 1 ). Dose-response curves, which allowed the identification of IC 50 by densitometry, confirmed the concentration-dependent PrP res inhibitory activity of compounds # 1-# 8 on Chandler-infected SN56 cells.
II. Mechanism of action of compounds
We investigated the mechanism of action of compounds # 1-# 8 and, since cellular PrP (PrP Effects of steroids on PrP levels. Since membranes are steroid-rich environments, we first evaluated whether the seven aminosteroids affect surface PrP. In order to assess the effect at this level, surface PrP was quantified by flow cytometry, after an overnight treatment with 10 mM each aminosteroid. Results were normalized to the PrP levels of DMSO-treated cells. In SN56 cells, compounds #4, #6 and budesonide decreased surface PrP c immunoreactivity. This reduction was associated with a decrease in total PrP (Fig. 3a) . To evaluate whether this decrease might be due to transcriptional changes, prnp expression was measured by qPCR after overnight compound treatment and no significant changes were observed (Fig. 3b) . Finally, in order to test whether this effect might be due to toxicity of the compounds at high concentrations, cells were treated overnight, and cell death and apoptosis were evaluated. Samples treated with compound #4 showed a limited increase in apoptotic cells, whereas the other tested molecules did not induce apoptosis (Fig. 3c) .
To understand the nature of this reduction at the cell surface, PrP binding was tested. PrP is bound to the cell surface via a glycosyl phosphatidylinositol (GPI) anchor, so it can be released by PI-PLC (Stahl et al., 1987) . PrP levels in cells that were treated overnight and incubated with PI-PLC were assessed by flow cytometry (Fig. 3d) . Cholesterol-, budesonide-and DMSO-treated cells presented similar PrP release effects after PI-PLC treatment (20 % of residual PrP after treatment). Membrane PrP release by PI-PLC was inhibited by compounds # 4 (50 % residual PrP) and # 6 (30 % residual PrP). Therefore, compounds #4 and #6 altered PrP binding at the cellular membrane, but # 1-# 3, # 5 and # 7 did not.
Fluorescence-based thermal shift assay to determine PrP rec stability. To determine whether these compounds interact directly with PrP proteins, we assessed PrP rec stability by thermal shift assay. Fluorescence increased with temperature and after the intensity peak was reached, there were gradual decreases, indicating possible protein aggregation or precipitation, or a drop of SYPRO Orange efficiency. The method was valid, since the observed melting temperatures (T m ), which were between 59 and 60 u C, were in the same range as those identified in other studies, such as for human PrP (fragment 121-230) by circular dichroism (Knowles & Zahn, 2006) or ovine PrP by differential scanning colorimetry (Rezaei et al., 2003) .
The compounds that presented anti-PrP rec activity were then tested, at different concentrations, for their effect on PrP rec . Since compound #4 greatly affected PrP levels and binding, it was compared with cholesterol, as a steroidal non-curing control (Bate et al., 2004) , but it did not affect the fluorescence derivative (Fig. 4a) , even at 100 mM. Nevertheless, at 50 mM, compound # 8 significantly reduced the T m of PrP by more than 0.8 u C compared with DMSO and erythromycin A. These modifications were not observed for compound # 8 incubated with SYPRO Orange alone and without PrP rec (data not shown). Therefore, in contrast with compound # 4, cholesterol and erythromycin A, compound # 8 interacts with PrP protein and may change its stability.
DISCUSSION
Many chemical libraries have been tested for their potential application to the field of prion diseases (Bach et al., 2003; Bertsch et al., 2005; Kocisko et al., 2003; Lorenzen et al., 2005) . We tested an innovative library that included not only chemical but also natural products. The tested molecules, which encompass diverse chemical structures, are well-identified and characterized by different techniques.
Our drug screening on Chandler-infected SN56 and in 22L-infected GT1-7 cells led to the identification of eight compounds. Their IC 50 values were consistent with those of compounds identified in other screens on infected cells (Kocisko et al., 2003) . The compounds presented here belong to classes never identified before in prion diseases: 3-aminosteroids and one derivative of erythromycin A (Fig. 2) . Their putative therapeutic applications will be assessed in the future by in vivo studies on infected rodents.
Steroids and prion diseases
Steroids have been implicated in the pathogenesis of prion diseases. Surface PrP c is found in lipid rafts or caveolae-like domains; its expression is cholesterol-dependent (Gilch et al., 2006; Rothberg et al., 1990; Vey et al., 1996) and drugs that deplete cholesterol inhibit PrP res accumulation (Bate et al., 2004; Prior et al., 2007; Taraboulos et al., 1995) .
Only a few steroids have been described which have activity against prions. Prednisone acetate, an anti-inflammatory steroid, affects the course of scrapie infection when injected at the time of infection (Outram et al., 1974) . In addition, previous high-throughput screening (Kocisko et al., 2003) identified three steroids: budesonide, chol-11-enic acid and chrysanthelin A. However, in silico screening of compounds resembling budesonide identified several other steroids, most of which were ineffective in cell culture (Lorenzen et al., 2005) .
Thus, for the first time, we describe the novel anti-prion activity of aminosteroids. All the identified steroids presented here have an amino, methylamino or dimethyl amino group at position C-3 (Fig. 2) . They differ mostly in the substituent at position C-17 and they all show PrP res inhibitory activity in a dose-dependent manner (Supplementary Fig. S2 and Table 1 ).
Proposed mechanism of action of steroidal compounds
PrP release experiments showed that compounds #4 and # 6 altered PrP binding, which may be a primary explanation for the PrP res clearance induced by these two aminosteroids. Indeed, altering PrP anchorage [by changing its transmembrane anchorage (Taraboulos et al., 1995) or by cholesterol depletion (Bate et al., 2004) ] leads to PrP res inhibition.
However, since budesonide and compounds #4 and #6 reduced PrP levels but budesonide did not alter PrP binding, a more general mechanism of action might be involved here. Actually, similar observations of posttranscriptional PrP reduction have been made for other anti-prion compounds, such as pentosan sulfate (Shyng et al., 1995) or suramin (Gilch et al., 2001) . Such PrP reduction may participate in altering the mechanism of PrP polymerization in infected cells (Aguib et al., 2008) .
Nevertheless, we did not observe any alteration in PrP levels for cells treated with compounds # 1, # 2, # 3, # 5 and #7, although they inhibited PrP res accumulation. The identified steroids might act by completely different mechanisms, but the high level of structural similarities of these compounds strongly suggests that they trigger a common target for prion inhibition. This common target, when activated or inhibited by steroids, and depending on the level at which it is modulated, could induce a reduction in PrP levels or a modification of PrP binding, either of which could interact with a target involved in the regulatory pathway of PrP c metabolism. As such, they might well be promising pharmacological tools for the identification of common steps leading to prion replication inhibition.
Anti-prion activity of the erythromycin A derivative
Erythromycin A has previously been proposed as a treatment for Alzheimer's disease (Tucker et al., 2005) but it was not an efficient inhibitor of PrP res replication in our cell culture system. We present here a derivative of this molecule which might be interesting for prion treatment. We observed a change in the shape of the T m curve and a reduction in PrP c stability when PrP-infected cells were incubated with the erythromycin A derivative, compound # 8. These results indicate that the interaction between PrP c and compound #8 leads to a peculiar conformation of PrP c , which could induce the alteration of its amyloidogenic properties and consequently lead to the inhibition of PrP res conversion (McCutchen et al., 1993; Pellarin & Caflisch, 2006) . Searching for compounds that interact with amyloid precursor stability, by using this newly described technique, might be a novel way to discover new therapeutic tools for amyloidosis diseases. Moreover, molecular characterization of amyloidogenic inhibition by interactions between PrP c and compound # 8 might allow a better understanding of the mechanism of prion replication.
Classical strategies for prion treatment are based on destabilizing the amyloid protein, i.e. PrP res , or targeting the level or trafficking of its precursor (Gilch et al., 2007; Tagliavini et al., 2000; Trevitt & Collinge, 2006) . Here, we propose a new strategy, based on the alteration of the stability of the amyloidogenic properties of the PrP res precursor, i.e. the normal PrP. Further experiments will encompass mutated PrPs, implied in familial forms of prion diseases, which are known to possess increased autoaggregation properties. Values that were significantly different by Student's t-test are indicated by asterisks (**P,0.05).
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Conclusions
We have identified eight compounds, belonging to chemical classes that have never been observed to have an effect on prion diseases, that inhibited PrP res accumulation in two cell cultures infected by two different prion strains. Our results suggest that the seven 3-aminosteroids and the previously described budesonide should trigger a common target, possibly implicated in the regulatory pathways of PrP c metabolism. The major steps in this pathway are as yet unknown, but they will be investigated using these steroids as new pharmacological tools. More generally, the role of steroids and aminosteroids in prion infection and curing, and their involvement in cellular pathways will be dissected. Finally, structure-activity relationships and comparisons between treating and nontreating aminosteroids will provide information on these pathways.
Interestingly, we found that an erythromycin A derivative not previously investigated for use in prion therapy directly interacted with PrP stability. Since familial forms of prion diseases are characterized by an aggregation-prone PrP, this compound could be a lead for a new prophylactic treatment of these human diseases. Furthermore, as levels of amyloidogenic precursors have been identified as factors in the phenomenon of amyloid replication previously, altering their stability by drug design experiments may provide new alternative strategies for the treatment of prion diseases or other neurodegenerative amyloidoses.
